Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma
Clinical trial NCT05789043 · RECRUITING
Trial details
- NCT number
- NCT05789043
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-21
- Primary completion
- 2026-08-15
- Enrollment
- 140
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.